A practical reference on GRF(1-29): what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
==== 2004–2008 ==== In June 2004 and again in December 2005, the JINR–LLNL collaboration strengthened their claim for the discovery of element 113 by conducting chemical experiments on 268Db, the final decay product of 288115. This was valuable as none of the nuclides in this decay chain were previously known, so that their claim was not supported by any previous experimental data, and chemical experimentation would strengthen the case for their claim, since the chemistry of dubnium is known. 268Db was successfully identified by extracting the final decay products, measuring spontaneous fission (SF) activities and using chemical identification techniques to confirm that they behave like a group 5 element (dubnium is known to be in group 5). Both the half-life and decay mode were confirmed for the proposed 268Db which lends support to the assignment of the parent and daughter nuclei to elements 115 and 113 respectively. Further experiments at the JINR in 2005 confirmed the observed decay data. In November and December 2004, the Riken team studied the 205Tl + 70Zn reaction, aiming the zinc beam onto a thallium rather than a bismuth target, in an effort to directly produce 274Rg in a cross-bombardment as it is the immediate daughter of 278113. The reaction was unsuccessful, as the thallium target was physically weak compared to the more commonly used lead and bismuth targets, and it deteriorated significantly and became non-uniform in thickness. The reasons for this weakness are unknown, given that thallium has a higher melting point than bismuth.
Features of the Advanced Lesion: Extension of the lesion into alveolar bone, periodontal ligament with significant bone loss Continued loss of collagen Cytopathic alterations in plasma cells in the absence of altered fibroblasts Formation of periodontal pocketing Conversion of bone marrow into fibrous connective tissue
NH3 + OCl− → NH2Cl + OH− NH2Cl + NH3 → N2H+5 + Cl− (slow) N2H+5 + OH− → N2H4 + H2O (fast) (The attacks by hydroxide and ammonia may be reversed, thus passing through the intermediate NHCl− instead.) The reason for adding gelatin is that it removes metal ions such as Cu2+ that catalyses the destruction of hydrazine by reaction with monochloramine (NH2Cl) to produce ammonium chloride and nitrogen. Hydrogen azide (HN3) was first produced in 1890 by the oxidation of aqueous hydrazine by nitrous acid. It is very explosive and even dilute solutions can be dangerous. It has a disagreeable and irritating smell and is a potentially lethal (but not cumulative) poison. It may be considered the conjugate acid of the azide anion, and is similarly analogous to the hydrohalic acids.
==== Grand Encampment ==== In 1914, the Grand Master of the Grand Encampment of the Knights Templar in the United States, Joseph K. Orr, visited Havana, where he found 50 members of the fraternity. In 1921, he authorized the formation of a Commandery and issued dispensation to the Havana Commandery U. D., K. T., where Walter M. Daniels was made Commander. General George M. Moulton made an inspection of the ranks, and the Havana Commandery received its charter on April 27, 1922. By 1951, they had 91 members.
Sources: en.wikipedia.org
The BNP test is used as an aid in the diagnosis and assessment of severity of heart failure. A recent meta-analysis concerning effects of BNP testing on clinical outcomes of patients presenting to the emergency department with acute dyspnea revealed that BNP testing led to a decrease in admission rates and decrease in mean length of stay, although neither was statistically significant. Effects on all cause hospital mortality was inconclusive. The BNP test is also used for the risk stratification of patients with acute coronary syndromes.
=== Coated microneedles === Coated MNs are fabricated by coating drug solution over solid MNs and the thickness of the drug layer can be adjusted depending on the amount of drug to be administered. A benefit of coated MNs is that less of the drug is needed as compared to other drug administration routes. This is because the layer of drug will quickly dissolve and delivered into the systemic circulation directly across the skin. The solid MNs which are removed afterwards may be contaminated by left-over drugs and the reuse of those MNs raise the concern of cross-infection between patients. Coated microneedles are often covered in other surfactants or thickening agents to assure that the drug is delivered properly. Some of the chemicals used on coated microneedles are known irritants. While there is risk of local inflammation to the area where the array was, the array can be removed immediately with no harm to the patient.
Wrinkles deepen, and forehead frown lines can be seen even when not frowning. Telangiectasias (spider veins) are most commonly seen around the nose, cheeks, and chin. Skin becomes leathery, and laxity occurs. Solar lentigines (age spots) appear on the face and hands. Possibly pre-cancerous red and scaly spots (actinic keratoses) appear. Cutaneous malignancies In addition to the above symptoms, photoaging can also result in an orderly maturation of keratinocytes and an increase in the cell population of the dermis, where abundant, hyperplastic, elongated, and collapsed fibroblasts and inflammatory infiltrates are found. Photodamage can also be characterized as a disorganization of the collagen fibrils that constitute most of the connective tissue, and the accumulation of abnormal, amorphous, elastin-containing material, a condition known as actinic elastosis.
Sources: en.wikipedia.org
== Bibliography == Audi, G.; Kondev, F. G.; Wang, M.; et al. (2017). "The NUBASE2016 evaluation of nuclear properties". Chinese Physics C. 41 (3). 030001. Bibcode:2017ChPhC..41c0001A. doi:10.1088/1674-1137/41/3/030001. pp. 030001-1–030001-17 pp. 030001-18–030001-138, Table I. The NUBASE2016 table of nuclear and decay properties Beiser, A. (2003). Concepts of modern physics (6th ed.). McGraw-Hill. ISBN 978-0-07-244848-1. OCLC 48965418. Hoffman, D. C.; Ghiorso, A.; Seaborg, G. T. (2000). The Transuranium People: The Inside Story. World Scientific. ISBN 978-1-78-326244-1. Kragh, H. (2018). From Transuranic to Superheavy Elements: A Story of Dispute and Creation. Springer. ISBN 978-3-319-75813-8. Zagrebaev, V.; Karpov, A.; Greiner, W. (2013). "Future of superheavy element research: Which nuclei could be synthesized within the next few years?". Journal of Physics: Conference Series. 420 (1) 012001. arXiv:1207.5700. Bibcode:2013JPhCS.420a2001Z. doi:10.1088/1742-6596/420/1/012001. ISSN 1742-6588. S2CID 55434734.
Things like ideologies, law, government, money and the economy are built on language; they exist because there are stories that billions of people believe. The current prevalence of misinformation suggests that an AI could use language to convince people to believe anything, even to take actions that are destructive. Geoffrey Hinton said in 2025 that modern AI is particularly "good at persuasion" and getting better all the time. He asks, "Suppose you wanted to invade the capital of the US. Do you have to go there and do it yourself? No. You just have to be good at persuasion." The opinions amongst experts and industry insiders are mixed, with sizeable fractions both concerned and unconcerned by risk from eventual superintelligent AI. Personalities such as Stephen Hawking, Bill Gates, and Elon Musk, as well as AI pioneers such as Geoffrey Hinton, Yoshua Bengio, Stuart Russell, Demis Hassabis, and Sam Altman, have expressed concerns about existential risk from AI. In May 2023, Geoffrey Hinton announced his resignation from Google in order to be able to "freely speak out about the risks of AI" without "considering how this impacts Google". He notably mentioned risks of an AI takeover, and stressed that in order to avoid the worst outcomes, establishing safety guidelines will require cooperation among those competing in use of AI. In 2023, many leading AI experts endorsed the joint statement that "Mitigating the risk of extinction from AI should be a global priority alongside other societal-scale risks such as pandemics and nuclear war".
=== Television === Mogo appears in the Batman: The Brave and the Bold episode "The Eyes of Despero!". Mogo appears in Green Lantern: The Animated Series, voiced by Kevin Michael Richardson. Mogo appears in the Mad segment "Does Someone Have to GOa?", voiced by Fred Tatasciore. Mogo and his debut story are referenced in the DC Universe series Lanterns, with Hal Jordan's vault being activated with the voice password "Mogo doesn't socialize".
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.